YZ129, a glioblastoma inhibitor, targets the HSP90-calcineurin-NFAT pathway by directly binding to heat shock protein 90 (HSP90) and exhibits an IC 50 of 820 nM on NFAT nuclear translocation. It induces cell-cycle arrest at the G2/M phase in GBM cells, leading to apoptosis and inhibiting tumor cell proliferation and migration [1].